Related Experiment Video
Updated: Jul 31, 2025
Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
Targeting ferroptosis as a promising therapeutic strategy to treat cardiomyopathy
Huiyan Sun1,2, Dandan Chen3, Wenjing Xin4
1Health Science Center, Chifeng University, Chifeng, China.
Insights
Ferroptosis, a cell death pathway involving iron, contributes to various cardiomyopathies. Inhibiting this process shows promise as a potential therapeutic strategy for heart muscle diseases.
Area of Science:
- Cardiology
- Molecular Biology
- Pathology
Background:
- Cardiomyopathies encompass diverse heart muscle diseases leading to heart failure and sudden cardiac death.
- The precise molecular mechanisms driving cardiomyocyte damage are not fully understood.
- Ferroptosis, a regulated cell death form dependent on iron and lipid peroxidation, is implicated in several cardiomyopathy types.
Purpose of the Study:
- To elucidate the role of ferroptosis in the pathogenesis of cardiomyopathies.
- To review therapeutic compounds targeting ferroptosis for cardiomyopathy treatment.
- To explore ferroptosis inhibition as a potential therapeutic strategy.
Main Methods:
- Literature review summarizing current research on ferroptosis and cardiomyopathies.
- Analysis of molecular mechanisms linking ferroptosis to cardiomyocyte damage.
- Evaluation of therapeutic compounds that inhibit ferroptosis.
Main Results:
- Ferroptosis contributes to ischemic, diabetic, doxorubicin-induced, and septic cardiomyopathies.
- Compounds inhibiting ferroptosis demonstrate therapeutic potential in preclinical models.
- Targeting ferroptosis offers a novel approach to managing heart muscle diseases.
Conclusions:
- Ferroptosis is a key mechanism in the development of various cardiomyopathies.
- Pharmacological inhibition of ferroptosis presents a promising therapeutic avenue for cardiomyopathy treatment.
- Further research into ferroptosis inhibitors could lead to effective treatments for heart failure.
Abstract:
Cardiomyopathies are a clinically heterogeneous group of cardiac diseases characterized by heart muscle damage, resulting in myocardium disorders, diminished cardiac function, heart failure, and even sudden cardiac death. The molecular mechanisms underlying the damage to cardiomyocytes remain unclear. Emerging studies have demonstrated that ferroptosis, an iron-dependent non-apoptotic regulated form of cell death characterized by iron dyshomeostasis and lipid peroxidation, contributes to the development of ischemic cardiomyopathy, diabetic cardiomyopathy, doxorubicin-induced cardiomyopathy, and septic cardiomyopathy. Numerous compounds have exerted potential therapeutic effects on cardiomyopathies by inhibiting ferroptosis. In this review, we summarize the core mechanism by which ferroptosis leads to the development of these cardiomyopathies. We emphasize the emerging types of therapeutic compounds that can inhibit ferroptosis and delineate their beneficial effects in treating cardiomyopathies. This review suggests that inhibiting ferroptosis pharmacologically may be a potential therapeutic strategy for cardiomyopathy treatment.
Related Concept Videos
01:16Necrosis
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
01:29Cardiomyopathy V: Interprofessional Care
01:26Heart Failure Drugs: Inotropic Agents